We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Biophytis | EU:ALBPS | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.0003 | -12.50% | 0.0021 | 0.0021 | 0.0022 | 0.0024 | 0.0021 | 0.0024 | 17,003,279 | 16:35:28 |
From May 2023 to May 2024
By Chris Wack
Biophytis shares fell 11% to $2.40 after the company said it has filed for a pre-submission meeting request with the Food and Drug Administration to discuss filing for emergency use authorization in the U.S. for Sarconeos in the treatment of Covid-19.
The stock dropped 13% on Wednesday after the company priced a registered direct offering valued at $3.8 million. The stock is down 74% in the past 12 months.
The biotechnology company said this request is a further key step in defining the conditions for rapid market access in the U.S. for Sarconeos, following a similar process initiated with the European Medicine Agency in May.
Biophytis said that depending on feedback from the FDA, it could consider filing an emergency use application by the end of 2023 or in the first half of 2024.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
July 20, 2023 13:06 ET (17:06 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Biophytis Chart |
1 Month Biophytis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
